Enterprise Therapeutics

Enterprise Therapeutics is a drug discovery company dedicated to the development of new therapies for respiratory diseases. Backed by top-tier venture capital investors, the company is headquartered in the UK with offices at the University of Sussex Innovation Centre.In diseases such as cystic fibrosis, asthma and COPD, the lungs become congested with mucus, leading to breathing difficulties. Enterprise Therapeutics’ scientific strategy aims to discover novel disease-modifying therapies that target the underlying mechanisms of mucus congestion, which will reduce the frequency of lung infections and improve patients' quality of life.These novel mucus-regulating therapies are achieved by targeting ion channels such as ENaC to increase mucus hydration and clearance. Enterprise has also identified novel targets and compounds that reduce mucus production, a complementary approach to mucus hydration therapies.